Clinical data on drug-eluting stents and alternative therapies have put a crimp in percutaneous coronary procedures, as medical therapy and coronary bypass have gained favor.Abbott faces an uphill battle in the diagnostics arena where it must go head-to-head against market leader Roche, along with
By Valuentum : Abbott ( NYSE : ABT ) has a track record that is unrivaled. The firm is more than 125 years old and remains aligned with favorable long-term healthcare
By Abba's Aces: The last time I wrote about Abbott Laboratories ( NYSE : ABT ) I stated: "Like I said, I will only be buying a small batch this time around, only for the dividend. I think the entire
Abbott Laboratories ( NYSE : ABT ) Q2 2014 Earnings Conference Call July 16, 2014 9:00 am ET Executives Miles White – Chairman, Chief Executive Officer Thomas Freyman
Abbott posted mixed second-quarter results that on balance slightly exceeded our expectations, but not enough to move the needle on our valuation. However, we do plan to modestly bump up our fair value estimate after incorporating the acquisitions of CFR and Veropharm, along with the divestment of
Abbott Laboratories ( ABT +0.2% ) Q2 results: Total Revenues: $5,551M (+1.9%); International Revs: $3,990M (+2.7%); U.S. Revs
July 16 (Reuters) - Abbott Laboratories : * CEO, in conference call, says growth for nutritional products, pharmaceuticals
July 16 (Reuters) - Abbott Laboratories Inc on Wednesday reported better than expected second quarter earnings, helped by strong sales of its medical diagnostics products.
PARIS, July 16 (Reuters) - Sanofi has held talks with Abbott Laboratories , Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs,...
Abbott Laboratories ( NYSE : ABT ): Q2 EPS of $0.54 beats by $0.03 . Revenue of $5.55B (+1.8% Y/Y) beats by $30M . Press Release Post your comment!